NOVARTIS

TAF MEK Lung - Home - HCP

Prescribing information

Image

Image

TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in Non-Small Cell Lung Cancer (NSCLC)

TAFINLAR in combination with MEKINIST is indicated in adult patients with advanced non-small cell lung cancer (NSCLC) with a *BRAF* V600 mutation.[1,2]

For the full safety profile, please refer to the Summary of Product Characteristics (SmPC) for TAFINLAR and MEKINIST.

Adverse event reporting: Details of how to report adverse events are available at

the bottom of the page. Please refer to the respective SmPC for all licensed indications.

TAFINLAR + MEKINIST is the first and only targeted treatment available for patients with *BRAF* V600-positive advanced NSCLC[1–3]

Why choose TAFINLAR + MEKINIST?

Image

In a retrospective analysis (N=36), treatment-naïve patients with *BRAF* V600E mutation had an overall response rate of 63.9% at Year 5[4]

Find out more

Image

It has a well established safety profile[1,2]

Find out more

Image

It offers oral dosing[1,2]

Find out more

BRAF V600E, mutation of the *BRAF* gene at valine (V) 600 to glutamate (E); NSCLC, non-small cell lung cancer; SmPC, summary of product characteristics.

References

1. Tafinlar (dabrafenib) Summary of Product Characteristics.

2. Mekinist (trametinib) Summary of Product Characteristics.

3. National Institute of Health and Care Excellence. Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer. Available at: https://www.nice.org.uk/guidance/ta898/chapter/1-Recommendations [Accessed June 2025].

4. Planchard D, et al. *J Thorac Oncol* 2022;17:103–115.

5. Planchard D, et al. *Lancet Oncol* 2017;18:1307–1316.

Efficacy

Efficacy

See more details

Hide details

Safety profile

Safety profile

See more details

Hide details

BRAF mutation and mechanism of action for TAFINLAR + MEKINIST

BRAF mutation and mechanism of action for TAFINLAR + MEKINIST

See more details

Hide details

Dosing and administration

Dosing and administration

See more details

Hide details

UK | June 2025 | FA-11217824

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.
